PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
• Segmentation by therapy area
• Comparison by therapy area
• Diabetes drugs – Market size and forecast 2017-2022
• Thyroid hormone disorder drugs – Market size and forecast 2017-2022
• hGH – Market size and forecast 2017-2022
• Testosterone replacement therapy – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by therapy area
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Association between obesity and endocrine disorders
• Use of biosimilars for endocrine disorders
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbvie
• Merck
• Novo Nordisk
• Pfizer
PART 16: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global pharmaceutical drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for diabetes
Exhibit 06: Pipeline molecules for hGH
Exhibit 07: Pipeline molecules for other endocrine disorders
Exhibit 08: Market definition – Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Annual global sales of leading endocrine disorder products 2015-2017
Exhibit 12: Global endocrinology drugs market – Market size and forecast 2017-2022 ($ bn)
Exhibit 13: Global endocrinology drugs market – Year over year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Bargaining power of suppliers
Exhibit 18: Threat of new entrants
Exhibit 19: Threat of substitutes
Exhibit 20: Threat of rivalry
Exhibit 21: Market condition – Five forces 2017
Exhibit 22: Global endocrinology drugs market by therapy area – Market share 2017-2022 (%)
Exhibit 23: Comparison by therapy area
Exhibit 24: Diabetes drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Diabetes drugs – Year over year growth 2018-2022 (%)
Exhibit 26: Thyroid hormone disorder drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Thyroid hormone disorder drugs – Year over year growth 2018-2022 (%)
Exhibit 28: hGH – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: hGH – Year over year growth 2018-2022 (%)
Exhibit 30: Testosterone replacement therapy – Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Testosterone replacement therapy – Year over year growth 2018-2022 (%)
Exhibit 32: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 33: Others – Year over year growth 2018-2022 (%)
Exhibit 34: Market opportunity by therapy area
Exhibit 35: Customer landscape
Exhibit 36: Global endocrinology drugs market by region – Market share 2017-2022 (%)
Exhibit 37: Regional comparison
Exhibit 38: Endocrinology drugs market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Endocrinology drugs market in Americas – Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in Americas
Exhibit 41: Endocrinology drugs market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Endocrinology drugs market in EMEA – Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in EMEA
Exhibit 44: Endocrinology drugs market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 45: Endocrinology drugs market in APAC – Year over year growth 2018-2022 (%)
Exhibit 46: Top 3 countries in APAC
Exhibit 47: Market opportunity
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Abbvie overview
Exhibit 53: Abbvie – Business segments
Exhibit 54: Abbvie – Organizational developments
Exhibit 55: Abbvie – Geographic focus
Exhibit 56: Abbvie – Segment focus
Exhibit 57: Abbvie – Key offerings
Exhibit 58: Merck overview
Exhibit 59: Merck – Business segments
Exhibit 60: Merck – Organizational developments
Exhibit 61: Merck – Geographic focus
Exhibit 62: Merck – Segment focus
Exhibit 63: Merck – Key offerings
Exhibit 64: Novo Nordisk overview
Exhibit 65: Novo Nordisk – Business segments
Exhibit 66: Novo Nordisk – Organizational developments
Exhibit 67: Novo Nordisk – Geographic focus
Exhibit 68: Novo Nordisk – Segment focus
Exhibit 69: Novo Nordisk – Key offerings
Exhibit 70: Pfizer overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings
【掲載企業】
Abbvie, Merck, Novo Nordisk, Pfizer